Adc Spi

Antibody Drug Conjugates Market Size, Share & Industry Growth Report ...

www.mordorintelligence.com

The Antibody Drug Conjugates Market worth USD 20.12 billion in 2026 is growing at a CAGR of 28.88% to reach USD 71.55 billion by 2031. F. Hoffmann-La Roche Ltd, Pfizer Inc. (Seagen Inc.), AstraZeneca plc, Gilead Sciences Inc. and Takeda Pharmaceutical Co. Ltd are the major companies operating in this market. Note: Market size and forecast figures in this report are generated using Mordor Intelligence’s proprietary estimation framework, updated with the latest available data and insights as of 2026. ... Worldwide cancer diagnoses reached 19.96 million in 2022, and models project 35 million annual cases by 2050[1]World Health Organization, “Cancer Data and Statistics,” WHO.int . Breast, lung, and colorectal cancers already anchor ADC approvals yet only 8% of eligible patients received an ADC in 2025, signaling significant headroom for the Antibody-Drug Conjugates market. Lung cancer incidence in China surpassed 800,000 cases in 2024, boosting demand for TROP2- and HER2-targeting conjugates. R&D spending on ADC platforms climbed 38% year-on-year to USD 12.4 billion in 2024. As of January 2026, 431 active ADC studies appear on ClinicalTrials.gov, including 83 Phase 3 trials in tumor types beyond breast and hematologic cancers. China’s science foundation earmarked USD 890 million in 2025 for domestic payload innovation, reducing reliance on auristatin imports. The Antibody Drug Conjugates Market size is expected to grow from USD 15.61 billion in 2025 to USD 20.12 billion in 2026 and is forecast to reach USD 71.55 billion by 2031 at 28.88% CAGR over 2026-2031. Continued migration away from broad-spectrum chemotherapy toward targeted biologics, faster U.S. regulatory review of drug–antibody ratio and linker stability, and 83 new clinical entrants during 2024 are reshaping oncology treatment pathways.

Antibody Drug Conjugates Market Size Report, 2026-2033

www.grandviewresearch.com

In January 2024, MediLink Therapeutics entered into a licensing and collaboration agreement with F. Hoffmann-La Roche Ltd. to advance the development of YL211, a next-generation antibody-drug conjugate (ADC). This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. In July 2022, trastuzumab deruxtecan achieved landmark results in HER2-low disease, while in June 2024, the TROPION-Breast01 study (Lancet Oncology) validated datopotamab deruxtecan (Datroway; AstraZeneca/Daiichi Sankyo), later approved in 2025 for HR+/HER2- breast cancer. Controlled-release formulations, such as the DXd payload, have improved potency-risk balance and regulatory acceptance. Rapid adoption in breast, lung, gastric, and urothelial cancers, combined with active pipelines for SN-38-based ADCs, indicates a sustained shift toward DNA-targeting payloads. In January 2024, Celltrion, Inc. and WuXi XDC entered into a Memorandum of Understanding (MoU) to collaborate on comprehensive antibody-drug conjugate (ADC) services, covering both development and manufacturing activities. In January 2024, Johnson & Johnson Services, Inc. completed the acquisition of Ambrx Biopharma, Inc., a company known for its proprietary antibody-drug conjugate (ADC) technology used in creating advanced cancer therapies.

Global ADC Technology Market Size and Trends 2040

www.rootsanalysis.com

The global ADC technology market, valued at USD 2.34 billion in 2025, is projected to reach USD 3.44 billion in 2026 and USD 9.51 billion by 2040, representing a 7.5% CAGR during the forecast period 2026 to 2040. General Manager (Research and Development), Brian Mendelsohn (Director of ADC Process Development and Tech Transfer), Large Company, US · Former Chief Business Officer, Small Company, Switzerland · In 2026, the third-generation of ADC technologies segment occupies the highest market share, and this trend is unlikely to change in the coming years. As per our ADC technology market analysis, in 2026, the chemical type of conjugation is likely to occupy a higher share in the overall market. Chemical conjugation continues to be the leading approach in the development of ADCs because of its established scalability, affordability, and clinical efficacy in approved treatments. It is interesting to note that this method enables reliable production of ADCs with consistent DAR. Moreover, we anticipate the market for chemoenzymatic conjugation technologies to witness a higher CAGR during the forecast period. In 2026, the cleavable segment occupies a higher ADC technology market size as they enable selective payload release within target cells via intracellular triggers, balancing plasma stability with efficient drug activation at tumor sites.

Antibody Drug Conjugate Market Size, Share to 2035

www.rootsanalysis.com

The global antibody drug conjugate market, valued at USD 15.29 billion in 2025, is projected to reach USD 18.69 billion in 2026 and USD 28.41 billion by 2035, representing a CAGR of 4.8% from 2026 to 2035. To learn more about this report, request a free sample copy · Antibody drug conjugates combine the target specificity of monoclonal antibodies with the cell-killing activity of potent cytotoxic payloads through chemical linkers. Advances in site-specific conjugation, linker chemistry, payload design, pharmacokinetics, and pharmacodynamics have positioned ADCs as a leading modality for treating a wide range of solid tumors and hematological malignancies. The antibody drug conjugates market is currently valued at USD 18.69 billion in 2026, and is projected to reach USD 28.41 billion by 2035. North America currently leads the market with a share of 62.3%. The ADC market is expected to grow at a compounded annual growth rate (CAGR) of 4.8% during the forecast period, till 2035. The USFDA and other regulatory authorities have approved 19 antibody-drug conjugates for therapeutic use, namely Adcetris, Aidixi, Akalux, Besponsa, Blenrep, Datroway, Elahere, Emrelis, Enhertu, Jiataile, Kadcyla, Lumoxiti, Mylotarg, Padcev, Polivy, Tivdak, Trastuzumab Rezetecan, Trodelvy and Zynlonta. Pharmaceutical R&D and business-development teams can use these perspectives to benchmark pipelines, target strategies, platform maturity, and licensing activity. Smaller and emerging ADC developers can also use the report to identify potential partners, manufacturing gaps, and commercialization pathways.

Antibody Drug Conjugates Market Size to Hit USD 34.80 Bn by 2035

www.precedenceresearch.com

Antibody Drug Conjugates Market (By Product: Kadcyla, Enhertu, Adcetris, Polivy, Trodelvy, Padcev, Besponsa, Elahere, Zylonta, Mylotarg, Tivdak, Others; By Antigen Target: HER2 Receptor, CD22, CD30, Trop-2, CD79B, CD19, CD33, Nectin-4, Tissue Factor, Others; By Antibody Generation: First Generation, Second Generation, Third Generation, Fourth Generation; By Linker Type: Cleavable Linkers, Non-Cleavable Linkers, Linker-less ADCs; By Payload Type: Monomethyl Auristatin E (MMAE), Calicheamicin, Maytansinoids, Duocarmycins, PBD Dimers, Others; By Linker Technology: VC Linker, Hydrazone Linker, Valine-Alanine Linker, Sulfo-SPDB Linker, Others; By Application; By Distribution Channel) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2026 to 2035 The global antibody drug conjugates market size is calculated at USD 12.69 billion in 2025 and is predicted to increase from USD 14.09 billion in 2026 to approximately USD 34.80 billion by 2035, expanding at a CAGR of 10.61% from 2026 to 2035. This growth is due to the rising prevalence of cancer and growing R&D activities for the development of novel ADCs by key players. The company focuses on expanding ADC indications and investing in targeted oncology therapies. ... F. Hoffmann-La Roche Ltd · In April 2026, C4 Therapeutics announced a collaboration with Roche to develop a cutting-edge cancer treatment, degrader-antibody conjugates (DACs). The collaboration was made to combine ADC technology with targeted protein degradation (TPD). (Source: https://www.indianpharmapost.com) In May 2026, Galux, an AI-driven drug discovery company, signed an investment and joint research agreement with an ADC developer, AimedBio, which aims to create a protein delivery platform capable of crossing the blood-brain barrier.

Antibody Drug Conjugates Market Size, Top Share, Demand | Industry ...

straitsresearch.com

For instance, Trodelvy’s U.S. sales nearly doubled in 2024, showcasing high market uptake. Moreover, the region also benefits from a strong supply chain network, developed clinical infrastructure, and faster adoption of ADCs as compared to other regions. Asis Pacific is emerging as the fastest-growing region with a CAGR of 12.7% from 2026-2034, owing to increasing local innovations, strong regulatory support, and expanding patient access. The global antibody drug conjugates market size is valued at USD 13.63 billion in 2025 and is anticipated to grow from USD 15.41 billion in 2026 to USD 34.87 billion by 2034, growing at a CAGR of 11.04% from 2026 to 2034. Increasing approvals of HER2-targeted therapies, strategic ADC development partnerships across Asia Pacific, and rising adoption of antibody drug conjugates for cancer treatment are driving robust growth in the market. The breast cancer segment dominated the market in 2025 and is anticipated to register the fastest CAGR of 12.4% during 2026-2034. This dominance is attributed to the high prevalence of breast cancer worldwide and the increasing number of ADC approvals for breast cancer treatment. Moreover, ongoing ADC approvals, with expanding applications in hematology and solid tumors, reflect growing clinical acceptance. to learn more about this report Download Free Sample Report ... The global antibody drug conjugates market size is valued at USD 13.63 billion in 2025 and is anticipated to grow from USD 15.41 billion in 2026 till USD 34.87 billion by 2034, growing at a CAGR of 11.04% from 2026-2034.